Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Randolph Hecht

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|February 20, 2026
Advancements in intratumoral therapies for liver tumorsSteven S Raman, Neal R Cutler, John J Sramek, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 16, 2014
A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancerAmy L Hill, Kirandeep K Sumra, Marcia M Russell, et al.
Clinical Colorectal Cancer|July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab aloneDaniel J Freeman, Todd Juan, Maureen Reiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trialFairooz F Kabbinavar, Joseph Schulz, Michael McCleod, et al.
Anticancer Research|March 10, 2015
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancerJ Randolph Hecht, Tony R Reid, Christopher R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancerOday Hamid, Mary L Varterasian, Scott Wadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.
BMC Cancer|July 10, 2020
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimensZev A Wainberg, Kynan Feeney, Myung Ah Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Tarek Chidiac, et al.
Nutrients|January 21, 2023
Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal CancerKayti Luu, Jason Y Ye, Venu Lagishetty, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|February 20, 2026
Advancements in intratumoral therapies for liver tumorsSteven S Raman, Neal R Cutler, John J Sramek, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|December 16, 2014
A single institution experience in compliance with universal screening for Lynch syndrome in colorectal cancerAmy L Hill, Kirandeep K Sumra, Marcia M Russell, et al.
Clinical Colorectal Cancer|July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab aloneDaniel J Freeman, Todd Juan, Maureen Reiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trialFairooz F Kabbinavar, Joseph Schulz, Michael McCleod, et al.
Anticancer Research|March 10, 2015
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancerJ Randolph Hecht, Tony R Reid, Christopher R Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancerOday Hamid, Mary L Varterasian, Scott Wadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.
BMC Cancer|July 10, 2020
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimensZev A Wainberg, Kynan Feeney, Myung Ah Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2008
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancerJ Randolph Hecht, Edith Mitchell, Tarek Chidiac, et al.
Nutrients|January 21, 2023
Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal CancerKayti Luu, Jason Y Ye, Venu Lagishetty, et al.
Pageof 9